Radiotherapy Market Outlook 2030: Growth Trends, Strategic Insights & Emerging Opportunities

Radiotherapy Market, valued at US$6.23 billion in 2022, is forecasted to grow at a robust CAGR of 4.9%, reaching US$7.21 billion in 2024 and an impressive US$9.62 billion by 2030. During the forecast years, the growth of the market is attributed to the focus on advancements in radiotherapy treatment technology growing patient population, increasing initiatives to promote radiotherapy awareness. Increasing use of particle therapy for cancer treatment among market players are also expected to support the growth of this market during the forecast period.

KEY PLAYERS IN THE RADIOTHERAPY MARKET INCLUDE

• Siemens Healthineers GmbH (Germany)
• Elekta (Sweden)
• Accuray Incorporated (US)
• IBA WORLDWIDE (Belgium)
• ViewRay Technologies, Inc (US)
• Perspective Therapeutics, Inc. (US)
• Hitachi High Tech Corporation (Japan)
• Sumitomo Heavy Industries Ltd. (Japan)
• Carl Zeiss Meditec AG (Germany)
• Koninklijke Philips N.V. (Netherlands)
• RaySearch Laboratories (Sweden)
• MIM Software Inc. (US)

Download an Illustrative overview

The 3D cameras (SGRT) segment is expected to register the highest growth in the forecast period of 2023-2028.

Based on the product, the radiotherapy systems are segmented into radiotherapy systems, software, 3D cameras (SGRT), and others. The radiotherapy systems segment commanded the largest share of the global robotic radiotherapy market in 2022, whereas the 3D cameras (SGRT) segment is projected to grow at the highest CAGR during the forecast period.

SGRT has gained widespread acceptance among cancer facilities worldwide due to its capacity to provide non-invasive, real-time, six-dimensional patient positioning and monitoring throughout radiation therapy treatment. This capability ensures precise treatment administration.

 SGRT presents a superior and swifter approach to treating brain tumors compared to invasive technologies or LINAC-based stereotactic radiosurgery. Its increasing adoption is attributed to its effectiveness in radiotherapy for breast cancer when combined with deep inspiration breath hold (DIBH) and voluntary-DIBH (VDIBH), which minimizes radiation-induced damage to the heart. Additionally, the expanding utilization of SGRT in whole-brain radiation therapy (WBRT) and the focus of industry players on introducing innovative 3D cameras and expanding their distribution networks are expected to bolster the growth of this segment in the foreseeable future.

The linear accelerators segment, by technology, is expected to register the market share of the global robotic radiotherapy market in 2023.

Based on technology, the global robotic radiotherapy market is segmented into linear accelerators, stereotactic radiation therapy systems, and particle therapy.

The linear accelerators segment is expected to account for the largest share of the indoor monitors market in 2023, primarily due to the significant advancements in recent years, enhancing their efficiency, precision, and versatility in delivering radiation therapy and ability to administer different types of radiation. Moreover, certain Linacs are equipped with onboard Cone Beam CT (CBCT) technology, facilitating real-time imaging prior to each treatment session. This guarantees accurate targeting, even in the presence of minor alterations in tumor position or patient anatomy. This represents another significant driver for the expansion of the market for fixed indoor monitors.

The lung cancer segment, by application, is expected to register the market share of the global robotic radiotherapy market in 2023.

Based on application, the global robotic radiotherapy market is segmented into prostate cancer, breast cancer, lung cancer, head & neck cancer, colorectal cancer, and other cancers. The lung cancer segment accounted for the largest share of the global robotic radiotherapy market in 2022. This segment is projected to reach USD 0.53 billion in 2028. The growth of the market primarily stems from the increasing occurrences of lung cancer, which may result in a greater caseload. Addressing this trend requires a focus on early detection, enhanced treatment alternatives, and concerted public health initiatives to alleviate the global burden of lung cancer. Additionally, contemporary lifestyles and dietary patterns are bolstering the expansion of this market segment.

Hospitals were the key end-users in the robotic radiotherapy market.

Based on end users, the robotic radiotherapy market is segmented into hospitals and independent radiotherapy centers.

Hospitals commanded the largest share of the global robotic radiotherapy market in 2022. The demand for radiotherapy systems among hospitals is driven by active government initiatives for effective testing, an increased number of research collaborations, and increased installation of robotic radiotherapy stations worldwide.

Request Sample Pages

North America is expected to be the largest market during the forecast period.

The radiotherapy market is divided into five key regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2023, North America, including the US and Canada, accounted for the largest market share, trailed by Europe. The North American region is witnessing growth due to the ongoing technological advancements, rising incidence of cancer, improving reimbursement scenario, and the rising focus of key players on strengthening market presence. On the other hand, the Asia Pacific market is expected to see the highest growth rate during the forecast period.

Recent Developments:

• In August 2024, Accuray received CE Mark for the new Helical Radiation Delivery System.
• In May 2024, Elekta launched AI-powered, adaptive CT-Linac, Evo, capable of delivering offline and online adaptive radiation therapy as well as improved standard IGRT treatments.
• In April 2024, Elekta and GE HealthCare's MIM Software entered significant collaboration to deliver leading cancer treatment planning solutions
• In April 2024, Accuray Incorporated expanded global training centre network with opening of the Accuray Innovation & Partnership Hub in Genolier, Switzerland.